five

Table 1_Noninvasive prescreening of pediatric adenoid hypertrophy using quantified MFCC statistics and clinical features: development and external validation.xlsx

收藏
NIAID Data Ecosystem2026-05-10 收录
下载链接:
https://figshare.com/articles/dataset/Table_1_Noninvasive_prescreening_of_pediatric_adenoid_hypertrophy_using_quantified_MFCC_statistics_and_clinical_features_development_and_external_validation_xlsx/31260592
下载链接
链接失效反馈
官方服务:
资源简介:
BackgroundAdenoid hypertrophy (AH) is a leading cause of pediatric obstructive sleep apnea, yet first-line diagnostics are invasive or resource-intensive. We developed and externally tested a low-cost, noninvasive screening model that fuses quantitative voice features with routine clinical variables for pre-endoscopy and primary-care triage. MethodsIn a dual-center cross-sectional study (N = 202), Center 1 (Capital Center for Children’s Health, Capital Medical University, n = 161) served as the development cohort and Center 2 (College of Otolaryngology Head and Neck Surgery, The 6th Medical Center, National Clinical Research Center for Otolaryngologic Diseases, Chinese PLA General Hospital, Beijing, China, n = 41) as the independent external cohort. Children produced sustained/a/phonations; Mel-frequency cepstral coefficients (MFCCs) were summarized into fixed statistics and combined with readily available clinical information. Modeling used patient-level aggregation with stratified 10-fold cross-validation in development. The final classifier was selected by a joint criterion of AUC and average precision (AP), then a single Youden-derived locked cutoff was determined in the development set and applied unchanged to the external cohort. Discrimination (AUC/AP), calibration (Brier score, slope, intercept), and clinical utility were evaluated. ResultsInternal performance was stable (AUC = 0.81; AP = 0.84). On the small external cohort, discrimination remained (AUC = 0.79; AP = 0.88). At the locked cutoff, the model achieved clinically actionable sensitivity/specificity with balanced F1. Calibration was acceptable (Brier = 0.20, slope = 0.71, intercept = 0.94). Decision-curve analysis showed positive net benefit across a wide range of threshold probabilities versus “treat-all” and “treat-none.” SHAP explainability indicated MFCC variability-related features and a subset of airway-symptom clinical variables as leading contributors, aligning with hyponasal resonance changes in AH. ConclusionA patient-level model with a locked decision threshold showed preservation of discrimination in a small external cohort, supporting a practical pathway for noninvasive, low-overhead AH triage prior to nasoendoscopy. Prospective multicenter studies are warranted.
创建时间:
2026-02-05
二维码
社区交流群
二维码
科研交流群
商业服务